Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy 글 내용 전체보기
Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company 글 내용 전체보기
Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial 글 내용 전체보기
Universal Health Services, Inc. To Present At The 37th Annual JP Morgan Healthcare Conference 글 내용 전체보기